Yusuf Uysal, MD, Salih Altun, MD, Güngör Sobacı, MD, M. Zeki Bayraktar, MD, Gülhane Medical Faculty Department of Ophthalmology, Ankara, Turkey

Purpose:

To evaluate the efficacy and safety of intravitreal injection of 4mg of triamcinolone acetonide for diffuse diabetic macular edema.

Methods:

Twenty five patients were unresponsive to laser photocoagulation in group I; fifteen patients without laser photocoagulation in group II prospectively evaluated. Visual outcomes were compared.

Results:

At least 3 months follow-up were obtained in the groups (range: 3 to12 months in group I, 3 to 8 months in group II). Visual benefit (visual acuity increase in 2 or more Snellen lines) from this treatment regimen were more common in patients with similar demographic properties, hemoglobin A1c values and clinical severity of macular edema (12/25 vs 12/15 :p=0.056). In total, 12 patients (30%) developed intraocular pressure (IOP) elevations at 1 to 4 weeks, which were controlled by glaucoma medications.

Conclusion:

Intravitreal injection is of benefit in eyes with diffuse diabetic macular edema, especially for eyes without prior laser photocoagulation. Medically controllable IOP elevations are not rare.